Recombinant Cynomolgus ALCAM/CD166 Fc Chimera Protein, CF

When Recombinant Cynomolgus Monkey ALCAM/CD166 Fc Chimera(Catalog # 10125-AL) is coated onto a microplate at 1 µg/mL, BiotinylatedRecombinant Human CD6 Fc Chimera binds with an ED50 of 10-60 ng/mL.

2μg/lane of Recombinant Cynomolgus Monkey ALCAM/CD166Fc Chimera (Catalog # 10125-AL)was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditionsand visualized by Coomassie® Blue staining, showing bands at 90-125 kDa and 180-250 kDa, respectively.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus ALCAM/CD166 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Cynomolgus Monkey ALCAM/CD166 Fc Chimera is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human CD6 Fc Chimera binds with an ED₅₀ of 10-60 ng/mL
• Source: Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey ALCAM/CD166 protein
  

  Cynomolgus Monkey ALCAM/CD166 (Trp28-Ala526) Accession # XP_005548303	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_005548303
• N-terminal Sequence: Trp28
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 82 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 90-125 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus ALCAM/CD166 Fc Chimera Protein, CF

• activated leucocyte cell adhesion molecule
• activated leukocyte cell adhesion moleculeFLJ38514
• ALCAM
• CD166 antigen
• CD166
• MEMDMGC71733

Background

ALCAM (activated leukocyte cell adhesion molecule), designated CD166, is a 100‑110 kDa type I transmembrane glycoprotein and a member of the Ig CAM family within the immunoglobulin superfamily (1). The cynomologous ALCAM amino acid sequence includes a signal peptide, an extracellular domain (ECD) with two V‑type and three C2‑type Ig‑like domains, a transmembrane domain and a short cytoplasmic domain (1). Human ALCAM has several isoforms, including an isoform lacking most of the cytoplasmic domain and a secreted isoform (sALCAM) which antagonizes full‑length ALCAM (2, 3). Mature cynomologous ALCAM ECD shares 93% and 96% amino acid sequence identity with human and mouse/rat ALCAM, respectively. ALCAM is expressed on multiple cell types including thymic epithelium, microvascular endothelium, activated lymphocytes and monocytes, and monocyte‑derived dendritic cells (1, 4). ALCAM mediates low‑affinity adhesion with itself or the cysteine‑rich scavenger receptor CD6 to regulate T cell development, immunological synapses (IS), and cell migration through endothelial junctions (1‑11). ALCAM on thymic epithelia mediates adhesion to CD6 on CD4⁺CD8⁺ T cells (6). Adhesion of ALCAM‑expressing antigen presenting cells and CD6‑expressing T cells stabilizes the early IS, while later it enhances CD3 effects on T cell proliferation, CD25 expression, and Th1 commitment (4, 7, 8). High ALCAM expression at the blood‑brain barrier in active multiple sclerosis, and its mouse model (EAE), promotes leukocyte migration to the brain (8, 9). High ALCAM expression on melanoma cell lines appears to be pro‑metastatic, but anti‑metastatic activity has been reported in breast cancer (3, 10, 11). ALCAM may influence expression or adhesion of the neuronal adhesion molecule NCAM‑L1, both in the developing retina and invasive melanoma (2, 12).

1. Bowen, M.A. et al. (1995) J. Exp. Med. 181:2213.
2. van Kilsdonk, J.W.J. et al. (2008) Cancer Res. 68:3671.
3. Ikeda, K. and T. Quertermous (2004) J. Biol. Chem. 279:55315.
4. Zimmerman, A.W. et al. (2006) Blood 107:3212.
5. van Kempen, L.C. et al. (2001) J. Biol. Chem. 276:25783.
6. Castro, M.A.A. et al. (2007) J. Immunol. 178:4351.
7. Nair, P. et al. (2010) Clin. Exp. Immunol. 162:116.
8. Masedunskas, A. et al. (2006) FEBS Lett. 580:2637.
9. Cayrol, R. et al. (2008) Nat. Immunol. 9:137.
10. Degen, W.G. et al. (1998) Am. J. Pathol. 152:805.

Bioinformatics

• Uniprot:
  • XP_005548303()